Rene Russo

Insider Reports History

Location
Waltham, MA
Signature
/s/ Kevin Brennan, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Rene Russo:

Form 4 holding Director

Adagio Therapeutics, Inc.

Security class
Common Stock
Shares / value
1,985,295
Estimated value
$7,841,915
Report date
05 Aug 2021
Price
$3.95
Ownership
Direct
Form 4 holding PRESIDENT AND CEO, Director

Xilio Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
88,500
Estimated value
$138,060
Report date
01 Jan 2026
Price
$1.04
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding PRESIDENT AND CEO, Director

Xilio Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
1,500,258
Estimated value
Report date
31 Dec 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Adagio Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
35,593
Estimated value
Report date
05 Aug 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

X4 Pharmaceuticals, Inc

Security class
Stock Option (right to buy)
Shares / value
6,000
Estimated value
Report date
02 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Rene Russo

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .